{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T05:21:22Z","timestamp":1778822482474,"version":"3.51.4"},"reference-count":60,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T00:00:00Z","timestamp":1648684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background and objective<\/jats:title><jats:p>This pilot study aimed to identify potential blood DNA methylation (BDM) biomarker genes for the diagnosis of liver fibrosis in non-alcoholic fatty liver disease (NAFLD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We included a total of 16 NAFLD patients with significant (SLF, liver fibrosis stage \u2265 2) and 16 patients with non-significant liver fibrosis (NSLF, fibrosis stages 0\u20131). The association between BDM and liver fibrosis was analyzed. Genes were selected based on a stepwise-filtering with CpG islands containing significant differentially methylated probes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The two groups of patients were distinguishable through both t-distributed stochastic neighbor embedding (t-SNE) analysis and unsupervised hierarchical clustering analysis based on their BDM status. BDM levels were significantly higher in the NSLF group than in the SLF group. The methylation levels in the island and shelf regions were also significantly higher in the NSLF group, as well as the methylation levels in the first exon, 3\u2032-untranslated region, body, ExonBnd, non-intergenic region, transcription start site (TSS)1500, and TSS200 regions (all <jats:italic>p<\/jats:italic> &amp;lt; 0.05). BDM status was associated with greater histological liver fibrosis, but not with age, sex, or other histological features of NAFLD (<jats:italic>p<\/jats:italic> &amp;lt; 0.05). The methylation levels of the hypomethylated CpG island region of <jats:italic>CISTR<\/jats:italic>, <jats:italic>IFT140<\/jats:italic>, and <jats:italic>RGS14<\/jats:italic> genes were increased in the NSLF group compared to the SLF group (all <jats:italic>p<\/jats:italic> &amp;lt; 0.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>BDM may stratify NAFLD patients with significant and non-significant liver fibrosis. The <jats:italic>CISTR<\/jats:italic>, <jats:italic>IFT140<\/jats:italic>, and <jats:italic>RGS14<\/jats:italic> genes are potential novel candidate BDM biomarkers for liver fibrosis and these pilot data suggest further work on BDM biomarkers is warranted.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2022.864570","type":"journal-article","created":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T11:43:17Z","timestamp":1648726997000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Potential Blood DNA Methylation Biomarker Genes for Diagnosis of Liver Fibrosis in Patients With Biopsy-Proven Non-alcoholic Fatty Liver Disease"],"prefix":"10.3389","volume":"9","author":[{"given":"Qing-Feng","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang-Jie","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei-Wu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang-Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-Lei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ou-Yang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher D.","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Targher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Yue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Guang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Hua","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1097\/CM9.0000000000000981","article-title":"From NAFLD to MAFLD: a \u201credefining\u201d moment for fatty liver disease.","volume":"133","author":"Zheng","year":"2020","journal-title":"Chin Med J."},{"key":"B2","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: a multisystem disease.","volume":"62","author":"Byrne","year":"2015","journal-title":"J Hepatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S2468-1253(21)00308-3","article-title":"Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis.","volume":"6","author":"Mantovani","year":"2021","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"B4","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases.","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology."},{"key":"B5","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement.","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/CM9.0000000000001263","article-title":"MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy.","volume":"134","author":"Xian","year":"2020","journal-title":"Chin Med J."},{"key":"B7","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.jhep.2021.05.003","article-title":"The Chinese society of hepatology position statement on the redefinition of fatty liver disease.","volume":"75","author":"Nan","year":"2021","journal-title":"J Hepatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.jhep.2017.07.027","article-title":"Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.","volume":"67","author":"Hagstr\u00f6m","year":"2017","journal-title":"J Hepatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.","volume":"61","author":"Ekstedt","year":"2015","journal-title":"Hepatology."},{"key":"B10","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/j.gastro.2018.04.034","article-title":"Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study.","volume":"155","author":"Vilar-Gomez","year":"2018","journal-title":"Gastroenterology."},{"key":"B11","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease.","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology."},{"key":"B12","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis.","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology."},{"key":"B13","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD.","volume":"45","author":"Angulo","year":"2007","journal-title":"Hepatology."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1136\/gut.2007.146019","article-title":"Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease.","volume":"57","author":"Harrison","year":"2008","journal-title":"Gut."},{"key":"B15","doi-asserted-by":"publisher","first-page":"615978","DOI":"10.3389\/fmed.2021.615978","article-title":"Liver fibrosis in non-alcoholic fatty liver disease: from liver biopsy to non-invasive biomarkers in diagnosis and treatment.","volume":"8","author":"Heyens","year":"2021","journal-title":"Front Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1080\/00365521.2019.1583366","article-title":"Non-invasive fibrosis scoring systems can predict future metabolic complications and overall mortality in non-alcoholic fatty liver disease (NAFLD).","volume":"54","author":"\u00d6nnerhag","year":"2019","journal-title":"Scand J Gastroenterol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1097\/cm9.0000000000000989","article-title":"Non-invasive fibrosis assessment in non-alcoholic fatty liver disease.","volume":"133","author":"Rios","year":"2020","journal-title":"Chin Med J."},{"key":"B18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S2468-1253(20)30308-3","article-title":"Non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis.","volume":"6","author":"Zhou","year":"2021","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"388","DOI":"10.21037\/hbsn-21-80","article-title":"Consensus scoring systems for nonalcoholic fatty liver disease: an unmet clinical need.","volume":"10","author":"Zhou","year":"2021","journal-title":"Hepatobiliary Surg Nutr."},{"key":"B20","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s13237-021-00367-y","article-title":"DNA methylation and regulation of gene expression: guardian of our health.","volume":"64","author":"Dhar","year":"2021","journal-title":"Nucleus."},{"key":"B21","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1042\/EBC20200009","article-title":"Making it or breaking it: DNA methylation and genome integrity.","volume":"64","author":"Sriraman","year":"2020","journal-title":"Essays Biochem."},{"key":"B22","doi-asserted-by":"publisher","first-page":"3905","DOI":"10.1038\/s41467-020-17673-9","article-title":"An integrative multi-omics analysis to identify candidate DNA methylation biomarkers related to prostate cancer risk.","volume":"11","author":"Wu","year":"2020","journal-title":"Nat Commun."},{"key":"B23","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nrurol.2013.89","article-title":"DNA methylation-based biomarkers in bladder cancer.","volume":"10","author":"Kandimalla","year":"2013","journal-title":"Nat Rev Urol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/978-981-15-4494-1_4","article-title":"DNA methylation in pulmonary fibrosis.","volume":"1255","author":"Zhou","year":"2020","journal-title":"Adv Exp Med Biol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"111319","DOI":"10.1016\/j.mad.2020.111319","article-title":"DNA methylation in Alzheimer\u2019s disease: in brain and peripheral blood.","volume":"191","author":"Wei","year":"2020","journal-title":"Mech Ageing Dev."},{"key":"B26","doi-asserted-by":"crossref","first-page":"8138","DOI":"10.3390\/ijms21218138","article-title":"DNA methylation in nonalcoholic fatty liver disease.","volume":"21","author":"Hyun","year":"2020","journal-title":"Int J Mol Sci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.2337\/DB18-1193","article-title":"DNA methylation signature of hepatic fat reveals a potential causal pathway for nonalcoholic fatty liver disease.","volume":"68","author":"Ma","year":"2019","journal-title":"Diabetes."},{"key":"B28","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1755-8794-5-5","article-title":"Global analysis of DNA methylation in early-stage liver fibrosis.","volume":"5","author":"Komatsu","year":"2012","journal-title":"BMC Med Genomics."},{"key":"B29","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.cellsig.2012.10.007","article-title":"DNA methylation: new therapeutic implications for hepatic fibrosis.","volume":"25","author":"Bian","year":"2013","journal-title":"Cell Signal."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.cellsig.2013.01.005","article-title":"DNA methylation and MeCP2 regulation of PTCH1 expression during rats hepatic fibrosis.","volume":"25","author":"Yang","year":"2013","journal-title":"Cell Signal."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/j.cellsig.2013.05.017","article-title":"New advances of DNA methylation in liver fibrosis, with special emphasis on the crosstalk between microRNAs and DNA methylation machinery.","volume":"25","author":"Bian","year":"2013","journal-title":"Cell Signal."},{"key":"B32","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13148-015-0056-6","article-title":"Differential DNA methylation of genes involved in fibrosis progression in non-alcoholic fatty liver disease and alcoholic liver disease.","volume":"7","author":"Zeybel","year":"2015","journal-title":"Clin Epigenet."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1136\/gutjnl-2016-311526","article-title":"Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease.","volume":"66","author":"Hardy","year":"2017","journal-title":"Gut."},{"key":"B34","doi-asserted-by":"publisher","first-page":"6946","DOI":"10.12659\/MSM.909747","article-title":"Altered DNA methylation sites in peripheral blood leukocytes from patients with simple steatosis and nonalcoholic steatohepatitis (NASH).","volume":"24","author":"Wu","year":"2018","journal-title":"Med Sci Monit."},{"key":"B35","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/oby.22667","article-title":"Association of hepatic global DNA methylation and serum one-carbon metabolites with histological severity in patients with NAFLD.","volume":"28","author":"Lai","year":"2020","journal-title":"Obesity (Silver Spring Md)."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1177\/2050640619868352","article-title":"Individualized risk prediction of significant fibrosis in non-alcoholic fatty liver disease using a novel nomogram.","volume":"7","author":"Zhou","year":"2019","journal-title":"United Eur Gastroenterol J."},{"key":"B37","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/liv.14251","article-title":"PNPLA3 rs738409 is associated with renal glomerular and tubular injury in NAFLD patients with persistently normal ALT levels.","volume":"40","author":"Sun","year":"2020","journal-title":"Liver Int."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease.","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"B39","doi-asserted-by":"publisher","first-page":"11077","DOI":"10.3748\/wjg.v21.i39.11077","article-title":"Liver fibrosis in non-alcoholic fatty liver disease \u2013 diagnostic challenge with prognostic significance.","volume":"21","author":"St\u00e5l","year":"2015","journal-title":"World J Gastroenterol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1093\/bioinformatics\/btt684","article-title":"ChAMP: 450k chip analysis methylation pipeline.","volume":"30","author":"Morris","year":"2014","journal-title":"Bioinformatics."},{"key":"B41","doi-asserted-by":"publisher","first-page":"e22","DOI":"10.1093\/nar\/gkw967","article-title":"Comprehensive characterization, annotation and innovative use of infinium DNA methylation BeadChip probes.","volume":"45","author":"Zhou","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1186\/1471-2105-11-587","article-title":"Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysis.","volume":"11","author":"Du","year":"2010","journal-title":"BMC Bioinformatics"},{"key":"B43","doi-asserted-by":"crossref","first-page":"Article3","DOI":"10.2202\/1544-6115.1027","article-title":"Linear models and empirical bayes methods for assessing differential expression in microarray experiments.","volume":"3","author":"Smyth","year":"2004","journal-title":"Stat Appl Genet Mol Biol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/nprot.2008.211","article-title":"Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources.","volume":"4","author":"Huang da","year":"2009","journal-title":"Nat Protoc."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1053\/j.gastro.2013.07.047","article-title":"Relationship between methylome and transcriptome in patients with nonalcoholic fatty liver disease.","volume":"145","author":"Murphy","year":"2013","journal-title":"Gastroenterology."},{"key":"B46","doi-asserted-by":"publisher","first-page":"953","DOI":"10.4161\/cc.4.7.1787","article-title":"RGS14 is a microtubule-associated protein.","volume":"4","author":"Martin-McCaffrey","year":"2005","journal-title":"Cell Cycle."},{"key":"B47","doi-asserted-by":"publisher","first-page":"11088","DOI":"10.3748\/wjg.v21.i39.11088","article-title":"Genetic background in nonalcoholic fatty liver disease: a comprehensive review.","volume":"21","author":"Macaluso","year":"2015","journal-title":"World J Gastroenterol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease.","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat Genet."},{"key":"B49","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/ng.2901","article-title":"Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease.","volume":"46","author":"Kozlitina","year":"2014","journal-title":"Nat Genet."},{"key":"B50","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/hep.27490","article-title":"Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease.","volume":"61","author":"Dongiovanni","year":"2015","journal-title":"Hepatology."},{"key":"B51","doi-asserted-by":"publisher","first-page":"e1001324","DOI":"10.1371\/journal.pgen.1001324","article-title":"Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits.","volume":"7","author":"Speliotes","year":"2011","journal-title":"PLoS Genet."},{"key":"B52","doi-asserted-by":"publisher","first-page":"6823","DOI":"10.3390\/ijms22136823","article-title":"RGS14 regulation of post-synaptic signaling and spine plasticity in brain.","volume":"22","author":"Harbin","year":"2021","journal-title":"Int J Mol Sci."},{"key":"B53","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1002\/hep.32133","article-title":"Regulator of G-protein signaling 14 protects the liver from ischemia-reperfusion injury by suppressing TGF-\u03b2-activated kinase 1 activation.","volume":"75","author":"Zhang","year":"2022","journal-title":"Hepatology."},{"key":"B54","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1177\/0022034517741283","article-title":"Essential role of IFT140 in promoting dentinogenesis.","volume":"97","author":"Li","year":"2018","journal-title":"J Dent Res."},{"key":"B55","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1369\/0022155419859357","article-title":"Expression of IFT140 during bone development.","volume":"67","author":"Zhang","year":"2019","journal-title":"J Histochem Cytochem."},{"key":"B56","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ajhg.2021.11.016","article-title":"Monoallelic IFT140 pathogenic variants are an important cause of the autosomal dominant polycystic kidney-spectrum phenotype.","volume":"109","author":"Senum","year":"2022","journal-title":"Am J Hum Genet."},{"key":"B57","doi-asserted-by":"publisher","first-page":"3990","DOI":"10.1172\/JCI65508","article-title":"A misplaced lncRNA causes brachydactyly in humans.","volume":"122","author":"Maass","year":"2012","journal-title":"J Clin Investig."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/j.jhep.2013.05.039","article-title":"Epigenetic modifications as new targets for liver disease therapies.","volume":"59","author":"Zeybel","year":"2013","journal-title":"J Hepatol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13148-016-0218-1","article-title":"DNA methylation profiling identifies novel markers of progression in hepatitis B-related chronic liver disease.","volume":"8","author":"Zeybel","year":"2016","journal-title":"Clin Epigenet."},{"key":"B60","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1055\/s-0040-1720980","article-title":"Comparison of DNA methylation profiles of hemostatic genes between liver tissue and peripheral blood within individuals.","volume":"121","author":"Olsson Lindvall","year":"2021","journal-title":"Thromb Haemost."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.864570\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T11:43:26Z","timestamp":1648727006000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.864570\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,31]]},"references-count":60,"alternative-id":["10.3389\/fmed.2022.864570"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.864570","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,31]]},"article-number":"864570"}}